Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Viking Therapeutics, Inc. (VKTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/26/2023 8-K Quarterly results
05/11/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "AMENDED AND RESTATED BYLAWSOFVIKING THERAPEUTICS, INC.,"
04/26/2023 8-K Quarterly results
04/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Viking Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, CA – April 3, 2023 – Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 2,586,300 additional shares of common stock. The gross proceeds to Viking from this offering are approximately $287.5 million, before deducting underwriting discounts and commissions and other estimated ..."
03/31/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"LEGAL OPINION",
"Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock SAN DIEGO, CA – March 29, 2023 – Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $250.0 million. In addition, Viking has granted the underwriters a 30-day option to purchase up to 2,586,300 additional shares of its common stock on the same terms and conditions. The offering is expected to close on or about April 3, ..."
03/28/2023 8-K Quarterly results
03/28/2023 8-K Quarterly results
02/08/2023 8-K Quarterly results
10/26/2022 8-K Quarterly results
07/27/2022 8-K Quarterly results
Docs: "Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update"
05/26/2022 8-K Quarterly results
04/27/2022 8-K Quarterly results
Docs: "Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update"
02/09/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
07/28/2021 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
05/21/2021 8-K Quarterly results
04/28/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
01/06/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/28/2020 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Ongoing • Phase 1 Trial Evaluating VK0214 for the Treatment of X-ALD Underway • Balance Sheet Remains Strong; Quarter-End Cash Approximately $255 Million SAN DIEGO, October 28, 2020 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2020, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended Septembe..."
07/29/2020 8-K Quarterly results
05/21/2020 8-K Submission of Matters to a Vote of Security Holders
04/30/2020 8-K Quarterly results
Docs: "Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH • New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL • IND Filing for VK0214 in X-ALD on Track for Mid-Year • Balance Sheet Remains Strong, Quarter-End Cash Approximately $270 Million SAN DIEGO, April 30, 2020 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2020, and provided an update on its clinical pipeline and other corporate developments. Highlights fr..."
03/17/2020 8-K Regulation FD Disclosure
11/05/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 8:30 a.m. ET today • IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH • Clinical Development of VK0214 for X-ALD Expected to Begin 1H20 • Balance Sheet Remains Strong with Approximately $290 Million in Cash SAN DIEGO, November 5, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended September 30, 2019, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter, and Subsequent to September 30, 2019..."
08/01/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Opinion of Paul Hastings LLP",
"At-The-Market Equity Offering Sales Agreement, by and among Viking Therapeutics, Inc., Stifel, Nicolaus & Company, Incorporated and Oppenheimer & Co. Inc"
08/01/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 • Continued Progress with VK0214 for X-ALD; Expect to Commence Phase 1 Clinical Study in 1H20 SAN DIEGO, August 1, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter ended June 30, 2019, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter, and Subsequent to June 30, 2019: “The second quarter ..."
07/02/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors"
05/23/2019 8-K Submission of Matters to a Vote of Security Holders
05/02/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily • Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Expected to Commence in 2H19 • IND Filing for VK0214 in X-ALD Planned in 2H19 SAN DIEGO, May 2, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2019, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter, ..."
03/13/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Additional VK2809 Phase 2 Data to be Presented at EASL 2019; Results Demonstrate Promising Efficacy at Doses as Low as 5 mg Daily • Initiation of Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Planned for 2H19 • Year-End Cash of Approximately $302 Million Provides Runway Through at Least 2021 SAN DIEGO, March 13, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2018, and provided an update on its clinical pip..."
09/21/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, by and between Viking Therapeutics, Inc. and William Blair & Company, L.L.C., as representative of the underwriters named therein",
"Opinion of Paul Hastings LLP",
"Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock"
09/18/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease and Elevated LDL-Cholesterol Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in LDL-C in Patients Receiving VK2809"
06/12/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Viking Therapeutics Announces Closing of Public Offering of Common Stock"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy